TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06053970

Intervention type: OTHER
Group type: OTHER
Intervention: Assessing postural responses induced by visual stimulation (Visual Evoked postural responses, VEPR)
Description: The intervention will last 60 minutes and will include an assessment of the Berg Balance Scale (BBS), the collection of stabilometric data, the collection of the numerical difficulty scale, the Fast Motion Sickness Scale (FMS) and will end with a break after exposure to VR.~The various conditions will be carried out in this order:~* Eyes open with VR headset simulating a static environment~* Eyes closed with VR helmet off~* Eight measurements on a stabilometry platform will be taken for each of the VR signals, in random order
Study: NCT05074862

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KetoneAid KE4 Pro Monoester
Description: A dietary supplement containing ketone monoester.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin and fat-based placebo
Description: Dosis isocaloric to the KetoneAid Arm
Study: NCT06332040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: random assignment to gentamicin or placebo bladder instillation to prevent CAUTI (catheterized urinary track infection)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gentamicin
Description: random assignment to gentamicin or placebo bladder instillation to prevent CAUTI (catheterized urinary track infection)
Study: NCT06221956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relevis
Description: Participants will receive access to the digital health intervention relevis in addition to TAU.
Study: NCT05256316

Intervention type: OTHER
Intervention: Previously admitted COVID-19 patients in intensive care units
Description: Exposure: this is a retrospective, observational study that does not include an intervention. Data collected for this study will be from previously hospitalized COVID-19 patients who had an intensive care unit stay during their admission
Study: NCT04297345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Blood enters the extracorporeal circuit from the arterial line of the femoral catheter. For this the investigators use a pump integrated in the monitor, equipped with control systems, exerting a negative pressure.~Subsequently, it enters the dialyzer through the internal part of the capillaries (porous), producing a passive exchange of inflammatory and oxidative substances (such as cytokines) with the dialysis fluid, which also circulates through the dialyzer, but through the external part of the capillaries. Blood is returned to the patient, through the venous line of the catheter, with a lower concentration of cytokines after passing through the dialyzer.~This circuit is repeated continuously during the 3 hours of the procedure to ensure maximum clearance of glutamate and interleukins, among other substances.
Study: NCT06196619

Intervention type: DIAGNOSTIC_TEST
Intervention: SWE:B-mode ultrasound and subcutaneous elastic modulus with shear wave elastography at three level
Description: Visual analog scale(VAS):This scale measure in which individuals rate their pain from 0 to 10, with 0 indicating no pain at all and 10 representing the worst pain;pain threshold through algometric measurement; quality of life using the EQ-5D general quality of life scale.

Intervention type: DIAGNOSTIC_TEST
Intervention: SWE:B-mode ultrasound and subcutaneous elastic modulus with shear wave elastography at three level
Description: Visual analog scale(VAS):This scale measure in which individuals rate their pain from 0 to 10, with 0 indicating no pain at all and 10 representing the worst pain;pain threshold through algometric measurement; quality of life using the EQ-5D general quality of life scale.

Intervention type: DIAGNOSTIC_TEST
Intervention: SWE:B-mode ultrasound and subcutaneous elastic modulus with shear wave elastography at three level
Description: Visual analog scale(VAS):This scale measure in which individuals rate their pain from 0 to 10, with 0 indicating no pain at all and 10 representing the worst pain;pain threshold through algometric measurement; quality of life using the EQ-5D general quality of life scale.
Study: NCT06397976

Intervention type: DEVICE
Intervention: ANTERION investigational
Description: Measurements from the investigational device ANTERION with software version 1.5 are to be compared against measurements from the ANTERION with software version 1.2.4 (cleared version)

Intervention type: DEVICE
Intervention: ANTERION investigational
Description: Measurements from the investigational device ANTERION with software version 1.5 are to be compared against measurements from the ANTERION with software version 1.2.4 (cleared version)
Study: NCT05116891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN04 (nadunolimab)
Description: FULLY HUMANISED MONOCLONAL ANTIBODY AGAINST IL1RAP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN04 (nadunolimab)
Description: FULLY HUMANISED MONOCLONAL ANTIBODY AGAINST IL1RAP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN04 (nadunolimab)
Description: FULLY HUMANISED MONOCLONAL ANTIBODY AGAINST IL1RAP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX
Description: mFOLFOX/CAN04

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTX
Description: DTX/CAN04

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G/C
Description: G/C/CAN04
Study: NCT04914767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella
Description: The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days.
Study: NCT05351905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil ( MPL-001)
Description: MPL-001: which is a 25:1 Cannabidiol (CBD): ∆9-tetrahydrocannabidiol (THC) oral formulation with a concentration of 50 mg/ml of CBD and 2 mg/ml of THC. The starting dose will be 1 mL per day (50 mg CBD) orally and gradually titrated to a maximum dose of 6 mL (300 mg CBD) per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDB+THC oil (MPL-005)
Description: MPL-005: which is a 5:1 Cannabidiol (CBD):∆9-tetrahydrocannabidiol (THC) oral formulation with a concentration of 25 mg/ml of CBD and 5 mg/ml of THC. The starting dose will be 1 mL per day (25 mg CBD + 5 mg THC) orally and gradually titrated to a maximum dose of 6 mL (150 mg CBD + 30 mg THC) per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: The starting dose will be 1 mL per day (contains no API) orally and gradually titrated to a maximum dose of 6 mL per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
Study: NCT06240624

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be given.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be given.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be given.
Study: NCT05644600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5055
Description: The subjects will be administered AZD5055 as single oral dose on Day 1 in the fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5055
Description: The subjects will be administered AZD5055 as single oral dose on Day 1 in the fasted state.
Study: NCT05947916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time Continuous Glucose Monitoring System
Description: The intervention group wore real-time CGM (120 cases) to monitor blood glucose, and was required to use real-time-CGM more than 50% of the time every 4 weeks, the more the better.
Study: NCT05976568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin injection
Description: 85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin injection
Description: 85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: 200 mg administered as IV infusion on Day 1 of each 21-day cycle
Study: NCT04691024

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Spinal stabilization exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Spinal stabilization exercises
Study: NCT05911113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sensory re-education training
Description: the patients will receive sensory re-education training in the form of texture discrimination training, limb position sense and tactile object recognition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional treatment
Description: the Patients in this group will receive traditional treatment in the form of proprioception neuromuscular facilitation (PNF) and graduated active and resisted wrist and hand muscle strengthening exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional treatment
Description: the Patients in this group will receive traditional treatment in the form of proprioception neuromuscular facilitation (PNF) and graduated active and resisted wrist and hand muscle strengthening exercises.
Study: NCT04269837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Receive sexual health counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05189704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: NSAID based patient-controlled analgesia will connected to intravenous line for pain control.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid
Description: Opioid based patient-controlled analgesia will connected to intravenous line for pain control.
Study: NCT06185478

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI scan
Study: NCT05446974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Competency Enhancement Training Program in PTSD Intervention
Description: This program was for nurses who work at the Mental Health Welfare Center and consisted of a workbook, self-learning online education, and workshop. It included a spoken audio track that was accompanied by visual prompts to provide knowledge on traumatic stress and introduce trauma recovery methods. Its online format made it convenient and widely accessible, and allowed for a low-intensity, cost-effective educational program. The program focused on providing self-learning guidelines for nurses to develop their capacity for PTSD intervention.
Study: NCT05263180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMB-09
Description: EMB-09 is a FIT-Ig® bispecific antibody against PD-L1 and OX40.
Study: NCT05691790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMA and patient activation intervention scheme
Description: Design of booklet for older people's preventive care: We propose that the booklet will include 8 main topics based on what experts and current academic literature believe are important for encouraging older people's preventive care utilization. To add the social norms-related cues for the later three topics of the booklet, one qualitative study on older adults who are active in preventive care is needed. Therefore, we will interview \~20 older adults aged 70 years or above who are active in taking preventive care. We will conduct one-to-one in-depth interview to explore how participants overcome difficulties during decision making for vaccination and their positive feelings after making achievements. We will also explore and identify older adults who have a positive future perspective.~Patient activation sections: . Four undergraduate medical students will be trained as the coaches to deliver the patient activation sections over six weeks. Each section will be around 20 min.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants in the control group will receive a pamphlet about recommendation for influenza, pneumococcal, and COVID-19 vaccines (if appropriate) for older people using information from Hong Kong Department of Health. As a control for the patient activation interviews, the control group will also be informed that they will join our telephone-based elderly care project by the end of the baseline assessment but instead of receiving the patient activation interviews, this group will receive six control telephone care visits over six weeks. Each control telephone care visit will be around 5-10 min during which the student helper will give general guidelines about dietary health and exercise for older people. The control messages are mainly educational and designed using information derived from the websites of Hong Kong Department of Health.
Study: NCT06483841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents as Partners
Description: The Parents as Partners program consists of 8 weekly group sessions attended by couples and was developed to strengthen the coparental relationship and promote paternal involvement. After consenting to their participation, couples will be randomly assigned to one of two conditions: intervention group or waitlist-control group. Participants will be assessed before and after the intervention on (co)parental, dyadic and work-family dimensions. Baseline (before intervention), post-test (2 months after baseline) and a follow-up assessment 6 months after the program will be performed. The intervention group will participate in the program, focusing on 5 family domains: Parents as Individuals; Parent-Child Relationships; Couple Relationship; Family of Origin Patterns; Stressors and Supports. Parents in the waitlist-control group will receive the intervention once their participation in the study is finished and if positive outcomes are found.
Study: NCT05297695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple therapy for H. pylori infection
Description: Triple therapy for H. pylori infection (Esomeprazole, Amoxicillin, and Clarithromycin) for two weeks
Study: NCT05661708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan
Description: Chitosan is a biodegradable, natural polyaminosaccharide with a nontoxic, non-allergenic, positively-charged polysaccharide derived from the deacetylation of chitin. Due to its molecular characteristics, chitosan has been used for improved hemostasis. Furthermore, chitosan has an antimicrobial and wound-healing effect
Study: NCT06510595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Treatment Arm
Description: Electrotherapy:~Transcutaneous Electrical Nerve Stimulation (TENS) will be placed across the fracture segments. The setting will be adjusted to 2±0.4 Hz sinusoidal wave, with a pulse width set between 50-200 microseconds, and each session will last between 20-30 minutes.~Active Elbow Flexion Exercise:~Following the electrotherapy session, the child will perform active assisted elbow flexion exercises with the forearm in a neutral position. This exercise will consist of 3 sets of 15 repetitions to enhance the role of the horizontal components of the brachioradialis muscle force.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Treatment Arm
Description: The child will wear a brace as a conservative treatment method.
Study: NCT05742841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moderate- or high-intensity statin/ rosuvastatin
Description: moderate- or high-intensity statin (either rosuvastatin 10mg daily or rosuvastatin 40 mg daily)
Study: NCT06438809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells (MSCs)
Description: MSC suspension single does injection.
Study: NCT06013839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talfirastide
Description: TXA127 (talfirastide) is a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II).
Study: NCT05535985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: treatment of pain or disease by inserting the tips of needles at specific points on the skin

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo acupuncture
Description: placebo acupuncture
Study: NCT05790044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: intra-oral infra-orbital nerve block with bupivacaine alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: intra-oral infra-orbital nerve block with bupivacaine and clonidine
Study: NCT06400589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanfanercept
Description: TNF inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanfanercept
Description: TNF inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Same composition as tanfanercept but without the active ingredient
Study: NCT05937256

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block type III
Description: Patients will be placed in lateral decubitus position with the side of the target stone facing up. After sterilization and draping of the skin, using US probe the block will be applied targeting the fascial plane between the quadratus lumborum and psoas major muscles (anterior aspect of the quadratus lumborum). After 20 min, sensory blockade will be evaluated with pinprick test, if loss of sensation is achieved at the T7-L1 dermatome site, the block is considered successful and patients will be transferred to ESWL Room.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Patients will be placed in the lateral decubitus position according to the selected site. After sterilization and draping of the skin, using US probe, the block will be applied in the plane deep to the erector spinae muscles and superficial to the transverse process. After 20 min, sensory blockade will be assessed with pinprick test, if loss of sensation is achieved at the T7-L1 dermatome site, the block is considered successful and patients is transferred to ESWL Room.
Study: NCT05063968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-6019 tablet
Description: Tablet is administered orally once on Day 1 and Day 9, respectively
Study: NCT05217719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin
Description: The dose of rhTPO is 15,000 U per day. The subcutaneous injection will be terminated when PCs are increased to normal. The duration of rhTPO will be 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients in the control group will receive the same amount of saline as a placebo, which is injected subcutaneously. The duration of saline will be 7 days.
Study: NCT04842565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab (200mg ivdrip D1 Q3W)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE will be performed by clinical demand, the interval between two TACEs is not less than 4 weeks.
Study: NCT06273930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% CALCIUM SODIUM PHOSPHOSILICATE
Description: Calcium sodium phosphosilicate is a particulate, bioactive glass material that degrades in the aqueous oral environment to release calcium and phosphate ions, leading to formation of hydroxycarbonate apatite on the dentine surface result in reduction in dentine hypersenstivity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8% Arginine
Description: Arginine contributes to Whole Mouth Health. It also plays a role with respect to dental caries, helping to maintain a pH-neutral environment, and is proven to rapidly help relieve dentin sensitivity. Arginine is truly a remarkable ingredient now being used in oral care products.
Study: NCT04711616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical therapy intervention
Description: physical therapy interventions include thermal therapy, electrical therapy, manual therapy, and therapeutic exercise.
Study: NCT06483568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pathways to Happiness Intervention
Description: Four weeks of activities including a gratitude journal, random acts of kindness, self-compassionate letter, and capitalizing on positive events activities.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Personal Organization Activities
Description: Four weeks of activities including a completed tasks journal, weekly task burst, productivity letter, and talking to others about task activities.